Company research
BioAtla, Inc.
CIK 1826892Updated Sep 24, 2026
BCAB price & chart
Loading TradingView…
NASDAQ:BCAB on TradingView ↗About the company
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has a robust pipeline consisting of ADCs and T cell engagers (TCEs) that utilize its conditionally active platform technology utilizing pH sensitivity to minimize on-target, off-tumor toxicity. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. To learn more about BioAtla, Inc., visit www.bioatla.com.
In the news
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets ↗
Recent filings
4 filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
10-Q filing
Submission of Matters to a Vote of Security Holders
Items 5.07
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 13,828,000Source | 52,422,000Source | 119,658,000Source | 225,736,000Source |
| Property, Plant and Equipment, NetUSD | 120,000Source | 678,000Source | 1,603,000Source | 2,728,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,118,000Source | 49,046,000Source | 111,471,000Source | 215,507,000Source |
| Assets, CurrentUSD | 8,013,000Source | 51,232,000Source | 116,406,000Source | 220,431,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 895,000Source | 2,186,000Source | 4,935,000Source | 4,924,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,532,000Source | 512,000Source | 1,495,000Source | 2,423,000Source |
| Other Assets, NoncurrentUSD | 163,000Source | 0Source | 154,000Source | 154,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 50,017,000Source | 38,157,000Source | 48,986,000Source | 45,397,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 5,000Source | 5,000Source |
| Additional Paid in CapitalUSD | 509,451,000Source | 500,298,000Source | 486,930,000Source | 473,135,000Source |
| Retained Earnings (Accumulated Deficit)USD | -545,646,000Source | -486,039,000Source | -416,263,000Source | -292,801,000Source |
| Stockholders' Equity Attributable to ParentUSD | -36,189,000Source | 14,265,000Source | 70,672,000Source | 180,339,000Source |
| Liabilities and EquityUSD | 13,828,000Source | 52,422,000Source | 119,658,000Source | 225,736,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 21,922,000Source | 14,540,000Source | 28,344,000Source | 23,131,000Source |
| Operating Lease, Liability, CurrentUSD | 1,427,000Source | 836,000Source | 1,624,000Source | 1,521,000Source |
| Accounts Payable, CurrentUSD | 8,194,000Source | 1,902,000Source | 3,819,000Source | 4,231,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,773,000Source | 0Source | 836,000Source | 2,460,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 1,162,000Source | 183,000Source | 545,000Source | 935,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 373,000Source | 925,000Source | 1,221,000Source | 1,199,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,434,000Source | 8,921,000Source | 13,544,000Source | 14,563,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -48,204,000Source | -71,936,000Source | -104,015,000Source | -90,420,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | 0Source | -98,000Source | -265,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,276,000Source | 9,511,000Source | 77,000Source | 61,213,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 7,118,000Source | 49,046,000Source | 111,471,000Source | 215,507,000Source |
| Additional Financial Items | ||||
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -185,000Source | 0Source | -2,000Source | -13,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 17,732,000Source | 21,848,000Source | 25,956,000Source | 28,793,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | 843,000Source | 3,369,000Source | 6,312,000Source | 1,648,000Source |
| Net Income (Loss) Attributable to ParentUSD | -59,607,000Source | -69,776,000Source | -123,462,000Source | -106,482,000Source |
| Operating ExpensesUSD | 61,305,000Source | 84,943,000Source | 129,687,000Source | 108,140,000Source |
| Other Nonoperating Income (Expense)USD | -302,000Source | 4,167,000Source | 6,225,000Source | 1,658,000Source |
| Payments of Financing CostsUSD | 897,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | 0Source | 9,215,000Source | 0Source | 61,682,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 0Source |
| Restructuring CostsUSD | 600,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -59,305,000Source | -73,943,000Source | -129,687,000Source | -108,140,000Source |
| Other Nonoperating Income (Expense)USD | -302,000Source | 4,167,000Source | 6,225,000Source | 1,658,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -59,607,000Source | -69,776,000Source | -123,462,000Source | -106,482,000Source |
| Earnings Per Share, BasicUSD per share | -1.01Source | -1.44Source | -2.58Source | -2.74Source |
| Earnings Per Share, DilutedUSD per share | -1.01Source | -1.44Source | -2.58Source | -2.74Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 58,827,934Source | 48,573,364Source | 47,777,568Source | 38,927,268Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 58,827,934Source | 48,573,364Source | 47,777,568Source | 38,927,268Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 17,732,000Source | 21,848,000Source | 25,956,000Source | 28,793,000Source |
| Interest ExpenseUSD | — | — | — | 0Source |
| Investment Income, InterestUSD | 843,000Source | 3,369,000Source | 6,312,000Source | 1,648,000Source |
| Operating ExpensesUSD | 61,305,000Source | 84,943,000Source | 129,687,000Source | 108,140,000Source |
| Research and Development ExpenseUSD | 43,573,000Source | 63,095,000Source | 103,731,000Source | 79,347,000Source |
| Restructuring CostsUSD | 600,000Source | — | — | — |
Filing attachments
bcab-ex99_1.htm · 8-K · 2026-04-02
EX-99.1 2 bcab-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CERTIFICATE OF MERGER MERGING BA MERGER SUB, INC. WITH AND INTO BIOATLA, INC. (Pursuant to Section 251 of the Delaware General Corporation Law) BioAtla, Inc., a corporation organized and existing under the Delaware General Corporation Law, does hereby certify: FIRST: The name and state of incorporation of each of the constituent corporations in the merger are: (i) BA Merger Sub, Inc., which is incorporated under the laws of the…
Read attachment ↗bcab-ex99_1.htm · 8-K · 2026-03-31
EX-99.1 2 bcab-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and business Highlights - Initiated a formal process to monetize assets - Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 - BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the…
Read attachment ↗bcab-ex99_2.htm · 8-K · 2026-03-31
EX-99.2 3 bcab-ex99_2.htm EX-99.2 Corporate Presentation March 2026 Conditionally Active Biologics: Transforming Cancer Therapy Important Notices & Disclaimers This presentation (the “Presentation”) by BioAtla, Inc. (“we”, “us”, “our”, “BioAtla”, or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to statements we make regard…
Read attachment ↗